Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Next Science Acne Cream is a topical therapeutic candidate developed by Next Science for the treatment of mild to moderate facial acne vulgaris. The formulation leverages the company's proprietary Xbio technology, which is engineered to disrupt and eliminate bacterial biofilms. Biofilms are protective matrices produced by bacteria such as *Cutibacterium acnes* (formerly *Propionibacterium acnes*) that contribute to antibiotic resistance and persistent inflammation in acne lesions. By breaking down the extracellular polymeric substance (EPS) matrix, the cream exposes the underlying bacteria, making them more susceptible to clearance. The product has been evaluated in Phase 2 clinical trials to assess its impact on lesion counts, investigator global assessment (IGA) scores, and patient quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Next Science Acne Cream.